alphaveMANKIND₹2,246.00

Mankind Pharma Ltd.

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹92,715 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	2,931.6	2,907.8	2,959.6	2,959.6
+ Capital Work-in-Progress	207.1	306.1	654.8	654.8
+ Investment Property	5.3	0.1	0.1	0.1
+ Goodwill	20.0	6,492.6	6,492.6	6,492.6
+ Other Intangibles	1,588.3	9,604.0	9,168.3	9,168.3
+ Intangibles under Development	74.7	519.5	472.9	472.9
+ Investments (Equity Method)	189.3	190.9	199.8	199.8
+ Non-current Investments	309.8	160.2	248.0	248.0
+ Other Non-current Financial Assets	29.5	200.3	64.5	64.5
Non-current Financial Assets	339.3	360.5	312.5	312.5
+ Deferred Tax Assets	80.4	107.9	324.7	324.7
+ Other Non-current Assets	66.3	92.3	352.0	352.0
Total Non-current Assets	5,313.0	20,581.8	20,937.1	20,937.1
Current Assets
+ Inventories	1,553.5	2,093.7	2,144.5	2,144.5
+ Current Investments	2,258.1	1,690.8	1,537.3	1,537.3
+ Trade Receivables	848.3	1,538.3	1,729.5	1,729.5
+ Cash & Cash Equivalents	382.0	407.4	391.7	391.7
+ Other Bank Balances	816.0	147.1	91.1	91.1
+ Short-term Loans	2.9	4.0	4.3	4.3
+ Other Current Financial Assets	13.2	301.4	247.9	247.9
Current Financial Assets	4,320.4	4,089.0	4,001.8	4,001.8
+ Other Current Assets	691.7	802.8	805.3	805.3
Total Current Assets	6,647.5	7,175.1	7,139.7	7,139.7
Total Assets	11,963.3	27,759.5	28,079.5	28,079.5
Equity
+ Equity Share Capital	40.1	41.3	41.3	41.3
+ Other Equity / Reserves	9,323.0	14,291.1	16,259.1	16,259.1
Equity — Owners of Parent	9,363.1	14,332.4	16,300.3	16,300.3
+ Minority Interest	212.7	235.8	260.7	260.7
Total Equity	9,575.8	14,568.2	16,561.1	16,561.1
Liabilities
+ Borrowings — Non-current	32.6	5,540.2	2,892.7	2,892.7
Non-current Financial Liabilities	32.6	5,540.2	2,892.7	2,892.7
+ Provisions — Non-current	123.1	155.1	248.7	248.7
+ Deferred Tax Liabilities	89.1	1,812.5	1,840.0	1,840.0
+ Other Non-current Liabilities	23.0	20.0	29.9	29.9
Non-current Liabilities	267.7	7,527.8	5,011.2	5,011.2
+ Borrowings — Current	174.6	2,971.2	3,418.9	3,418.9
+ Trade Payables	1,103.0	1,133.4	1,341.3	1,341.3
+ Other Current Financial Liab	235.5	674.2	749.5	749.5
Current Financial Liabilities	1,513.1	4,778.8	5,509.7	5,509.7
+ Provisions — Current	389.3	663.9	813.7	813.7
+ Current Tax Liabilities	46.4	18.1	10.9	10.9
+ Other Current Liabilities	170.9	202.8	172.9	172.9
Current Liabilities	2,119.7	5,663.6	6,507.3	6,507.3
Total Liabilities	2,387.5	13,191.4	11,518.5	11,518.5
Total Equity & Liabilities	11,963.3	27,759.5	28,079.5	28,079.5
Assets — additional as-filed lines
+ Non-current Assets Held for Sale	2.7	2.7	2.7	2.7
+ Current Tax Assets	82.0	189.5	188.2	188.2
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	86.3	148.7	148.7
+ Dues to Other Creditors — Current	—	1,047.1	1,192.6	1,192.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.